Myelodysplastic Syndromes
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndromes.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2018-08-10Clinical Trial Update: Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure [Phase 2]
Phase II add-on study evaluating vorinostat with azacitidine in higher-risk myelodysplastic syndrome patients after azacitidine failure; the…
-
CLINICAL_TRIALS trial_result · 2018-08-09Clinical Trial Update: Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes [Phase 1]
Phase 1 trial investigating volasertib with or without azacitidine in myelodysplastic syndromes; trial terminated with results posted in 201…
-
CLINICAL_TRIALS trial_result · 2018-08-07Clinical Trial Update: PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS [Phase 2]
Phase II trial update of 5-Azacytidine plus valproic acid (and eventually ATRA) in intermediate II and high-risk myelodysplastic syndromes; …
-
CLINICAL_TRIALS trial_result · 2018-07-30Clinical Trial Update: Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia [Phase 1]
Phase 1 trial evaluating volasertib in combination with azacitidine in Japanese patients with myelodysplastic syndromes or chronic myelomono…
-
CLINICAL_TRIALS trial_result · 2018-07-26Clinical Trial Update: Biological Predictive Factors of Response to ESA in Low Risk MDS Patients [Phase 4]
A Phase 4 trial investigating biological predictors of response to erythropoiesis-stimulating agents in low-risk myelodysplastic syndromes h…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2018-07-05Clinical Trial Update: Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation [Phase 1]
Phase 1 trial update reporting completion of a study evaluating ultra-low-dose interleukin-2 as graft-versus-host disease prophylaxis in hap…
-
CLINICAL_TRIALS trial_result · 2018-07-03Clinical Trial Update: E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes [Phase 2]
Phase 2 clinical trial evaluating E7070 in combination with idarubicin and cytarabine for relapsed acute myeloid leukemia and high-risk myel…
-
CLINICAL_TRIALS trial_result · 2018-06-04Clinical Trial Update: Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS [Phase 1, Phase 2]
Dose-escalation study of OXi4503 as a single agent and in combination with cytarabine, with subsequent Phase 2 cohorts planned for acute mye…
-
CLINICAL_TRIALS trial_result · 2018-05-31Clinical Trial Update: Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS) [Phase 2]
Phase 2 clinical trial evaluating clofarabine plus low-dose cytarabine in higher-risk myelodysplastic syndromes has completed and results we…
-
CLINICAL_TRIALS trial_result · 2018-05-11Clinical Trial Update: Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia [Phase 2]
Phase 2 trial evaluating azacitidine plus arsenic trioxide in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia; t…
-
CLINICAL_TRIALS trial_result · 2018-04-26Clinical Trial Update: Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS) [Phase 2]
A Phase 2 trial evaluating azacitidine plus deferasirox (ICL670) for higher-risk myelodysplastic syndromes has been terminated.
-
CLINICAL_TRIALS trial_result · 2018-04-13Clinical Trial Update: Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes [Phase 1, Phase 2]
A phase 1/2 trial evaluating clofarabine, cytarabine, and G-CSF in patients with myelodysplastic syndromes has been terminated, with results…
-
CLINICAL_TRIALS trial_result · 2018-04-10Clinical Trial Update: Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies [Phase 2]
A Phase 2 trial evaluated haplotype-mismatched hematopoietic stem cell transplantation in patients with hematological malignancies. The stud…
-
CLINICAL_TRIALS trial_result · 2018-04-03Clinical Trial Update: Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia [Phase 2]
Phase 2 trial evaluating a conditioning regimen of busulfan, fludarabine phosphate, and anti-thymocyte globulin followed by donor stem cell …
-
CLINICAL_TRIALS trial_result · 2018-04-03Clinical Trial Update: Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer [Phase 2]
Phase 2 clinical trial evaluating busulfan, cyclophosphamide, and antithymocyte globulin followed by stem cell transplant for hematologic ca…
-
CLINICAL_TRIALS trial_result · 2018-03-16Clinical Trial Update: Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies [Phase 2]
Phase 2 trial of non-myeloablative HLA-mismatched ex-vivo T-cell depleted stem cell transplantation for hematologic malignancies was termina…
-
CLINICAL_TRIALS trial_result · 2018-03-02Clinical Trial Update: Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT [NA]
A completed clinical trial evaluated cyclophosphamide and busulfan as conditioning before allogeneic hematopoietic stem cell transplantation…
-
CLINICAL_TRIALS trial_result · 2018-02-28Clinical Trial Update: Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) [Phase 2]
A Phase 2 trial of intensive chemotherapy with or without volasertib in newly diagnosed high-risk myelodysplastic syndrome and acute myeloid…
-
CLINICAL_TRIALS trial_result · 2018-01-29Clinical Trial Update: Paricalcitol in Treating Patients With Myelodysplastic Syndrome [Phase 2]
Phase 2 clinical trial evaluating paricalcitol in patients with myelodysplastic syndrome; study completed.
-
CLINICAL_TRIALS trial_result · 2018-01-16Clinical Trial Update: Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT [Phase 2]
Phase 2 trial evaluating post-transplant cyclophosphamide as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell …
-
CLINICAL_TRIALS trial_result · 2018-01-12Clinical Trial Update: Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating decitabine followed by mitoxantrone, etoposide, and cytarabine in adults with relapsed/refractory acute …
-
CLINICAL_TRIALS trial_result · 2018-01-03Clinical Trial Update: Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS [Phase 2]
Phase 2 trial update of azacitidine plus lenalidomide in elderly patients with previously treated acute myeloid leukemia and high-risk myelo…
-
CLINICAL_TRIALS trial_result · 2018-01-02Clinical Trial Update: Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome [NA]
Clinical trial update on cyclophosphamide and busulfan followed by donor stem cell transplant for myelofibrosis, AML, or myelodysplastic syn…
-
CLINICAL_TRIALS trial_result · 2017-12-15Clinical Trial Update: Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q [Phase 2]
Phase 2 trial evaluating lenalidomide combined with azacitidine in intermediate-2 or high-risk myelodysplastic syndromes with deletion 5q; s…
-
CLINICAL_TRIALS trial_result · 2017-12-12Clinical Trial Update: A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS) [Phase 3]
Phase 3 trial evaluating eltrombopag or placebo in combination with azacitidine for intermediate-1 to high-risk myelodysplastic syndromes wa…